Free Trial
NASDAQ:ETNB

89bio (ETNB) Stock Price, News & Analysis

$8.40
-0.53 (-5.94%)
(As of 11:51 AM ET)
Today's Range
$8.26
$9.01
50-Day Range
$8.25
$13.52
52-Week Range
$6.57
$22.93
Volume
255,235 shs
Average Volume
1.11 million shs
Market Capitalization
$826.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.14

89bio MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
235.8% Upside
$28.14 Price Target
Short Interest
Bearish
10.93% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.03mentions of 89bio in the last 14 days
Based on 12 Articles This Week
Insider Trading
Acquiring Shares
$20.72 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.42) to ($3.06) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.21 out of 5 stars

Medical Sector

537th out of 920 stocks

Pharmaceutical Preparations Industry

251st out of 427 stocks

ETNB stock logo

About 89bio Stock (NASDAQ:ETNB)

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

ETNB Stock Price History

ETNB Stock News Headlines

89bio (NASDAQ:ETNB) Stock Rating Reaffirmed by HC Wainwright
Financial Contrast: 89bio (NASDAQ:ETNB) vs. Eyenovia (NASDAQ:EYEN)
89bio Inc Ordinary Shares
Oppenheimer Reaffirms Their Hold Rating on 89bio (ETNB)
BofA raises 89bio to stock buy amid MASH outlook
See More Headlines
Receive ETNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/15/2024
Today
5/22/2024
Next Earnings (Estimated)
8/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ETNB
Fax
N/A
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.14
High Stock Price Target
$37.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+215.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-142,190,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.19 per share

Miscellaneous

Free Float
95,629,000
Market Cap
$878.53 million
Optionable
Optionable
Beta
1.15
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Rohan PalekarMr. Rohan Palekar (Age 58)
    CEO & Director
    Comp: $1.06M
  • Mr. Quoc Le-Nguyen (Age 56)
    Chief Technical Operations Officer
    Comp: $702.87k
  • Dr. Harry Mansbach M.D. (Age 59)
    Chief Medical Officer
    Comp: $732.87k
  • Mr. Ryan Stephen Martins (Age 45)
    Chief Financial Officer
  • Mr. Shiva K. Natarajan CPA (Age 58)
    Senior Vice President of Finance & Principal Accounting Officer
  • Ms. Annie J. Chang M.B.A.
    VP of Investor Relations & Corporate Communications
  • Ms. Amanda Kurihara
    Vice President of People & Culture
  • Ms. Melissa Abel
    Senior Vice President of Commercial Strategy
  • Mr. Paul Shin
    Senior Vice President of R&D Operations
  • Mr. Michael Baldwin
    VP & Head of Quality

ETNB Stock Analysis - Frequently Asked Questions

Should I buy or sell 89bio stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ETNB shares.
View ETNB analyst ratings
or view top-rated stocks.

What is 89bio's stock price target for 2024?

7 analysts have issued 12-month price targets for 89bio's shares. Their ETNB share price targets range from $14.00 to $37.00. On average, they expect the company's stock price to reach $28.14 in the next twelve months. This suggests a possible upside of 235.8% from the stock's current price.
View analysts price targets for ETNB
or view top-rated stocks among Wall Street analysts.

How have ETNB shares performed in 2024?

89bio's stock was trading at $11.17 at the beginning of the year. Since then, ETNB shares have decreased by 25.0% and is now trading at $8.38.
View the best growth stocks for 2024 here
.

When is 89bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our ETNB earnings forecast
.

How were 89bio's earnings last quarter?

89bio, Inc. (NASDAQ:ETNB) released its earnings results on Wednesday, May, 15th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by $0.08. During the same period last year, the firm earned ($0.54) earnings per share.

What ETF holds 89bio's stock?

AdvisorShares Dorsey Wright Micro-Cap ETF holds 2,900 shares of ETNB stock, representing 0.92% of its portfolio.

What other stocks do shareholders of 89bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), RTX (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO).

When did 89bio IPO?

89bio (ETNB) raised $70 million in an initial public offering (IPO) on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

Who are 89bio's major shareholders?

89bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (12.98%), Janus Henderson Group PLC (12.81%), Vanguard Group Inc. (4.96%), Redmile Group LLC (2.30%), Westfield Capital Management Co. LP (2.27%) and University of Wisconsin Foundation (0.51%). Insiders that own company stock include Edward Morrow Atkinson III, Kathleen Laporte, Michael R Hayden, Ollin B Sykes, Orbimed Advisors Llc, Quoc Le-Nguyen, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins.
View institutional ownership trends
.

How do I buy shares of 89bio?

Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ETNB) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners